- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.09. | Cyclerion cycles through latest pivot, reinventing itself as neuro biotech | 4 | FierceBiotech | ||
| 23.09. | Cyclerion sichert sich MIT-Lizenz für Programm gegen therapieresistente Depressionen | 1 | Investing.com Deutsch | ||
| 23.09. | Cyclerion signs MIT license for treatment-resistant depression program | 1 | Investing.com | ||
| CYCLERION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 23.09. | Cyclerion stock soars after MIT licensing deal to relaunch company | 1 | Investing.com | ||
| 23.09. | Cyclerion Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.09. | Cyclerion Therapeutics, Inc.: Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company | 109 | GlobeNewswire (Europe) | - Cyclerion Relaunches, Advancing a Phase 2-Ready Program for Millions Living with Treatment-Resistant Depression Through MIT License Agreement - - Webcast to be held September 24, 2025 at 10:30 a.m.... ► Artikel lesen | |
| 05.08. | Cyclerion Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 18.06. | Cyclerion Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.05. | Cyclerion Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.05. | Cyclerion Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 05.12.24 | Pre-market Movers: PainReform, Bluejay Diagnostics, Psyence Biomedical, Cyclerion Therapeutics, Verint Systems | 864 | AFX News | OVERLAND PARK (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.25 A.M. ET).In the Green PainReform Ltd. (PRFX) is up over 142% at... ► Artikel lesen | |
| 27.11.24 | Pre-market Movers: Primega Group, HWH International, Cyclerion Therapeutics, Interactive Strength, Infobird | 1.090 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.15 A.M. ET).In the Green HWH International Inc. (HWH) is up over 69% at $1.04.
Cyclerion... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,470 | -1,56 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
| EVOTEC | 6,698 | -0,86 % | Adidas, Bechtle, Bitcoin Group, Evotec, Renk, Ströer - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| BIONTECH | 87,85 | -2,77 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,455 | -7,62 % | Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference | ||
| INTELLIA THERAPEUTICS | 20,610 | -6,45 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 52,91 | -0,56 % | Apogee Therapeutics sichert sich 323,3 Mio. US-Dollar durch Aktienplatzierung an der NASDAQ | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 10,190 | +8,29 % | Oppenheimer senkt Kursziel für Moonlake Immunotherapeutics nach durchwachsenen Studienergebnissen | ||
| VIKING THERAPEUTICS | 29,300 | -3,19 % | Why Shares in Viking Therapeutics Surged This Week | ||
| 89BIO | 14,825 | -0,17 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 62,00 | -4,62 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
| TOURMALINE BIO | 47,880 | +0,08 % | Novartis Pharma AG: Novartis announces commencement of tender offer to acquire Tourmaline Bio | Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis ("Purchaser"), has commenced a tender offer... ► Artikel lesen | |
| MODERNA | 22,965 | -3,45 % | AstraZeneca ups investment in Virginia; Moderna vets launch VC fund | ||
| BEAM THERAPEUTICS | 26,210 | -5,96 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
| JYONG BIOTECH | 56,12 | +4,96 % | Jyong Biotech Ltd.: Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS-8 for Prostate Cancer Prevention | New Taipei City, Taiwan, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company", "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen | |
| OCUGEN | 1,467 | -7,65 % | Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25%... ► Artikel lesen |
Das Unternehmen CYCLERION THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,270 Euro und damit -10,28 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYCLERION THERAPEUTICS INC finden Sie auf Wallstreet Online.